Diabetic neuropathy: An intensive review

被引:246
作者
Duby, JJ
Campbell, RK
Setter, SM
White, JR
Rasmussen, KA
机构
[1] Univ Arizona, Tucson, AZ 85721 USA
[2] Washington State Univ, Coll Pharm, Dept Pharmacotherapy, Pullman, WA 99164 USA
[3] Washington State Univ, Coll Vet Med, Pullman, WA 99164 USA
关键词
amitriptyline; analgesics and antipyretics; anticonvulsants; antidepressants; antiinflammatory agents; antioxiclants; antiparkinson agents; antitussives; bupropion; caffeine; capsaicin; cardiac drugs; central nervous system stimulants; citalopram; classification; clonidine; desipramine; dextromethorphan; diabetic neuropathies; dihydroergotamine; enzyme inhibitors; epidemiology; erythromycin; fludrocortisone; fluoxetine; gabapentin; gastrointestinal drugs; hypotensive agents; lamotrigine; levodopa; macrolides; metoclopramide; mexiletine; midodrine; octreotide; opiates; oxcarbazepine; paroxetine; phenytoin; ruboxistaurin; steroids; cortico-; sympatholytic agents; sympathomimetic agents; thioctic acid; tramadol; transcutaneous electric nerve stimulation; venlafaxine; zonisamide;
D O I
10.1093/ajhp/61.2.160
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The epidemiology, classification, pathology, and treatment of diabetic neuropathy are reviewed. Summary. Diabetic peripheral neuropathy is a common complication of diabetes that can cause significant morbidity and mortality. Some 30% of hospitalized and 20% of community-dwelling diabetes patients have peripheral neuropathy; the annual incidence rate is approximately 2%. The primary risk factor is hyperglycemia. Sensorimotor neuropathy is marked by pain, paresthesia, and sensory loss. Cardiac autonomic neuropathy (CAN) may contribute to myocardial-infarction, malignant arrhythmia, and-sudden death. Gastroparesis is the most debilitating complication of gastrointestinal autonomic neuropathy. Genitourinary autonomic neuropathy can cause sexual dysfunction and neurogenic bladder. The pathology of diabetic neuropathy involves oxidative stress, advanced glycation end products; polyol pathway flux, and protein kinase C activation; all contribute to microvascular disease and nerve dysfunction. For symptom management current evidence from clinical trials supports the use of desipramine, amitriptyline, capsaicin, tramadol, gabapentin, bupropion, and venlafaxine as preferred medications. Citalopram, nonsteroidal antiinflammatory drugs, and opioid analgesics may be used as adjuvant agents. Lamotrigine, oxcarbazepine, paroxetine, levodopa, and alpha-lipoic acid are alternatives considerations. Evidence supporting the use of zonisamide, fluoxetine, mexiletine, dextromethorphan, and phenytoin is considered equivocal. Complementary therapies have also shown efficacy. The symptoms of CAN may be ameliorated with fludrocortisone, clonidine, midodrine, dihydroergotamine or caffeine, octreotide, and beta-blockers. Gastroparesis may be treated with metoclopramide or erythromycin. The most promising disease-modifying therapy is ruboxistaurin, which is in Phase III trials. Glycemic control remains the foundation of prevention and the prerequisite of adequate treatment. Conclusion. Diabetic neuropathy is a many-faceted complication of diabetes that can be managed symptomatically with an array of drugs.
引用
收藏
页码:160 / 173
页数:14
相关论文
共 90 条
[1]   Risk factors for diabetic peripheral sensory neuropathy - Results of the Seattle Prospective Diabetic Foot Study [J].
Adler, AI ;
Boyko, EJ ;
Ahroni, JH ;
Stensel, V ;
Forsberg, RC ;
Smith, DG .
DIABETES CARE, 1997, 20 (07) :1162-1167
[2]   Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus - A randomized controlled trial [J].
Backonja, M ;
Beydoun, A ;
Edwards, KR ;
Schwartz, SL ;
Fonseca, V ;
Hes, M ;
LaMoreaux, L ;
Garofalo, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (21) :1831-1836
[3]   Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials [J].
Backonja, M ;
Glanzman, RL .
CLINICAL THERAPEUTICS, 2003, 25 (01) :81-104
[4]   Use of anticonvulsants for treatment of neuropathic pain [J].
Backonja, MM .
NEUROLOGY, 2002, 59 (05) :S14-S17
[5]   Role of oxidative stress in diabetic complications - A new perspective on an old paradigm [J].
Baynes, JW ;
Thorpe, SR .
DIABETES, 1999, 48 (01) :1-9
[6]  
Bernstein G, 2000, DIABETES SPECTRUM, V13, P11
[7]  
Beydoun Ahmad, 2002, Expert Opin Pharmacother, V3, P59, DOI 10.1517/14656566.3.1.59
[8]   Sildenafil citrate: A therapeutic update [J].
Boyce, EG ;
Umland, EM .
CLINICAL THERAPEUTICS, 2001, 23 (01) :2-23
[9]   RELATIONSHIP OF ENDONEURIAL CAPILLARY ABNORMALITIES TO TYPE AND SEVERITY OF DIABETIC POLYNEUROPATHY [J].
BRITLAND, ST ;
YOUNG, RJ ;
SHARMA, AK ;
CLARKE, BF .
DIABETES, 1990, 39 (08) :909-913
[10]   Biochemistry and molecular cell biology of diabetic complications [J].
Brownlee, M .
NATURE, 2001, 414 (6865) :813-820